Showing 5011-5020 of 5909 results for "".
- Practitioners Should Be Aware of Mask-Associated Dry Eye (MADE)https://modernod.com/news/core-alerts-practitioners-to-mask-associated-dry-eye-made/2478221/Widespread use of face masks has been determined essential to combat COVID-19’s spread, yet is giving rise to a new phenomenon: increased reports of dry eyes. Experts from the Centre for Ocular Research & Education (CORE) are advising eye care professionals on how to recognize mask-associated
- RegeneRx Joint Venture Expects to Complete Phase 3 Dry Eye Trial in November 2020https://modernod.com/news/regenerx-joint-venture-expects-to-complete-phase-3-dry-eye-trial-in-november-2020/2478222/RegeneRx Biopharmaceuticals announced that its US joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome. According to GtreeBNT, the ARISE-3 trial was delayed a few months due to COVID-19; h
- Hospitals Could Be Facing Lower Patient Volumes For a While due to COVID-19. How Are They Responding?https://modernod.com/news/hospitals-could-be-facing-lower-patient-volumes-for-a-while-due-to-covid-19-how-are-they-responding/2478223/Patient volumes at hospitals have rebounded after major dips in March and April due to the COVID-19 pandemic. But new data show they are still below pre-pandemic levels and could stay there for a while, according to a FierceHealthcare
- Topcon Announces the US Launch of Aladdin-Mhttps://modernod.com/news/topcon-announces-the-us-launch-of-aladdin-m/2478217/Topcon Healthcare announced that it has launched its new Aladdin-M instrument in the US market. Aladdin-M combines corneal topography, pupillometry, and optical biometry to enable objective measurement of corneal curvature, pupil dynamics, and axial length metrics. The all-in-one Aladdin-M
- Vision Expo to Host Virtual Career Zone Event on September 22https://modernod.com/news/vision-expo-to-host-virtual-career-zone-event-on-september-22/2478215/Vision Expo announced plans to host the Virtual Career Zone, a virtual networking event designed to connect young professionals and students with prominent optical companies. Set to take place on Tuesday, September 22 from 11-11:55 a.m. EDT, the virtual event is inspired by Vision Expo’s o
- Moderna’s COVID-19 Vaccine Candidate Shows Promise in Older Adultshttps://modernod.com/news/modernas-covid-19-vaccine-candidate-shows-promise-in-older-adults/2478211/Interim data from a phase 1 study presented by Moderna showed that its experimental vaccine mRNA-1273 was safe and generated an immune response in people over the age of 55. Results from cohorts of older adults aged 56 to 70 years, as well as elderly participants 71 years and older, were detailed
- CooperVision Announces Direct-to-Consumer Campaign Featuring Sarah Michelle Gellarhttps://modernod.com/news/coopervision-announces-direct-to-consumer-campaign-featuring-sarah-michelle-gellar/2478209/CooperVision announced popular US television actress, producer, and entrepreneur Sarah Michelle Gellar as the spokesperson for its Brilliant Futures Myopia Management Program. Brilliant Futures is built around MiSight 1 day, the first and only soft contact lens FDA-approved to slow the progressio
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- Sight Sciences Announces Positive Interim Results From Trial of the OMNI Surgical System in Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-positive-interim-results-from-trial-of-the-omni-surgical-system-in-open-angle-glaucoma/2478205/Sight Sciences announced positive 6-month interim safety and efficacy results from a prospective, multicenter, historically controlled clinical trial of the OMNI Surgical System in open-angle glaucoma (OAG). The OMNI Surgical System is currently cleared for use for the delivery of small amounts o
- FDA Approves Cystadrops for the Ocular Manifestations of Cystinosishttps://modernod.com/news/fda-approves-cystadrops-for-the-ocular-manifestations-of-cystinosis/2478201/Recordati Rare Diseases announced the FDA has approved Cystadrops (cysteamine ophthalmic solution 0.37%), a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis. Cystadrops demonstrated a significant reduction in cystine crystal deposits i